Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03140943
Recruitment Status : Recruiting
First Posted : May 4, 2017
Last Update Posted : November 6, 2017
Sponsor:
Collaborators:
The Australasian Leukaemia & Lymphoma Group (ALLG)
International Myeloma Foundation
Celgene
Information provided by (Responsible Party):
National University Hospital, Singapore

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 1, 2019
Estimated Study Completion Date : June 1, 2022